Study guide

8.2 Vasodilators & Antianginal Agents

AACN Cardiac Medicine Certification CMC

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview and the CMC Test Plan

1.1 CMC Exam Format, Eligibility, Fees & Scoring 1.2 The CMC Test Plan: Four Domains and How to Study Them

2 Chapter 2: Acute Coronary Syndromes and Ischemic Heart Disease

2.1 Pathophysiology & Classification of Acute Coronary Syndromes 2.2 12-Lead ECG Localization & Cardiac Biomarker Trajectories 2.3 Acute Reperfusion Strategies & Nursing Management 2.4 Complications of Acute Myocardial Infarction 2.5 Chronic Coronary Disease, Hyperlipidemia and Lipid-Lowering Therapy

3 Chapter 3: Heart Failure, Cardiomyopathies, Pericardial and Valvular Disease

3.1 Acute Decompensated Heart Failure & Staging 3.2 Acute Cardiogenic Pulmonary Edema 3.3 Dilated, Hypertrophic, and Restrictive Cardiomyopathies 3.4 Acute Pericarditis, Cardiac Tamponade & Constrictive Pericarditis 3.5 Infective Endocarditis, Myocarditis and Rheumatic Heart Disease 3.6 Valvular Heart Disease: Stenosis & Regurgitation 3.7 Syncope: Cardiac Versus Non-Cardiac Causes and Workup

4 Chapter 4: Dysrhythmias, Conduction Disorders and Electrophysiologic Interventions

4.1 Atrial Fibrillation, Atrial Flutter & Supraventricular Tachycardias 4.2 Ventricular Arrhythmias & Cardiac Arrest Management 4.3 Atrioventricular Blocks & Intraventricular Conduction Delays 4.4 Temporary Pacing: Transcutaneous, Transvenous and Epicardial 4.5 Permanent Pacemakers, CRT and Device Troubleshooting 4.6 Implantable and Wearable Cardioverter Defibrillators 4.7 Catheter Ablation and Post-Ablation Nursing Care 4.8 Synchronized Cardioversion and Defibrillation

5 Chapter 5: Vascular Conditions and Vascular Interventions

5.1 Aortic Dissection, Aortic Aneurysms & Hypertensive Crises 5.2 Peripheral Artery Disease & Acute Limb Ischemia 5.3 Acute Venous Thrombosis, DVT and VTE Prophylaxis 5.4 Peripheral and Carotid Angiography and Interventions 5.5 Endovascular Aortic Repair: EVAR and TEVAR 5.6 Catheter-Directed Thrombolysis and Post-Intervention Vascular Complications

6 Chapter 6: Shock States and Mechanical Circulatory Support

6.1 Cardiogenic Shock Pathophysiology, Hemodynamics & Etiologies 6.2 Non-Cardiogenic Shock: Hypovolemic, Distributive and Obstructive 6.3 Multisystem Organ Dysfunction Syndrome 6.4 Intra-Aortic Balloon Pump Therapy & Waveform Optimization 6.5 Percutaneous & Surgical Mechanical Circulatory Support: Impella, VA-ECMO, LVAD

7 Chapter 7: Cardiac Procedures and Structural Heart Interventions

7.1 Diagnostic Cardiac Catheterization & Coronary Angiography Interpretation 7.2 Percutaneous Coronary Intervention: Stents, No-Reflow and Post-PCI Care 7.3 Structural Heart Interventions: TAVR, MitraClip, Pericardiocentesis 7.4 Post-Cardiac Surgery Management (>48 Hours) & Late Complications

8 Chapter 8: Cardiovascular Pharmacology

8.1 Inotropes, Vasopressors & Inodilators 8.2 Vasodilators & Antianginal Agents 8.3 Antiarrhythmic Agents: Vaughan Williams Classes I-IV 8.4 Anticoagulants, Antiplatelets, Thrombolytics & Reversal Agents 8.5 Diuretics and Decongestion Strategies 8.6 Guideline-Directed Medical Therapy for Heart Failure

9 Chapter 9: Non-Cardiovascular Conditions: Pulmonary

9.1 Acute Pulmonary Embolism 9.2 Acute Respiratory Failure and ARDS 9.3 Pleural Space Abnormalities: Pneumothorax, Effusion and Hemothorax 9.4 Pulmonary Hypertension and Right Ventricular Failure 9.5 Sleep-Disordered Breathing in Cardiac Patients

10 Chapter 10: Non-Cardiovascular Conditions: Endocrine, Renal, Hematologic, Neurologic and Behavioral

10.1 Diabetes Mellitus and Glycemic Control in Cardiac Care 10.2 Thyroid and Adrenal Disorders in the Cardiac Patient 10.3 Metabolic Syndrome and Cardiometabolic Risk 10.4 Coagulopathies: Heparin-Induced Thrombocytopenia, DIC and Bleeding Disorders 10.5 Anemia and Transfusion Management in Cardiac Patients 10.6 Acute Ischemic and Hemorrhagic Stroke in the Cardiac Patient 10.7 Acute Kidney Injury and Contrast-Associated Nephropathy 10.8 Chronic Kidney Disease and the Dialysis-Dependent Cardiac Patient 10.9 Electrolyte Imbalances and Dysrhythmia Risk 10.10 Substance Use, Withdrawal and Cardiac Effects 10.11 Non-Cardiac Chest Pain: Differential and Triage 10.12 Non-Cardiovascular Multisystem Complications in Cardiac Patients

11 Chapter 11: Monitoring and Diagnostics

11.1 Pulmonary Artery Catheterization & Hemodynamic Waveform Interpretation 11.2 Arterial Line Monitoring, Continuous Cardiac Output & ScvO2 11.3 Echocardiography, Cardiac MRI & Non-Invasive Cardiac Imaging 11.4 Stress Testing and Myocardial Perfusion Imaging 11.5 Remote Cardiovascular Monitoring and Ambulatory Rhythm Devices 11.6 Laboratory Testing in Cardiac Care 11.7 Arterial Blood Gases and Acid-Base Interpretation 11.8 Pulse Oximetry, Capnography and Chest Radiography

12 Chapter 12: Respiratory, Renal and Multisystem Therapeutic Interventions

12.1 Non-Invasive Ventilation in Cardiac Patients 12.2 Invasive Mechanical Ventilation and Heart-Lung Interactions 12.3 Renal Replacement Therapy: Hemodialysis, CRRT, SCUF and Ultrafiltration 12.4 Targeted Temperature Management After Cardiac Arrest 12.5 Palliative and End-of-Life Care in Advanced Cardiac Disease

8.2 Vasodilators & Antianginal Agents

Key Takeaways Explain This Topic AI

Nitroglycerin acts predominantly as a venodilator at low doses (<100 mcg/min) to reduce preload and myocardial oxygen demand, requiring non-PVC tubing due to drug absorption and a nitrate-free interval to prevent nitrate tolerance.

Sodium Nitroprusside provides balanced, rapid arterial and venous vasodilation for hypertensive crises and acute regurgitant valve lesions, but carries risk of cyanide toxicity (metabolic acidosis, elevated lactate, venous hyperoxia) and thiocyanate toxicity during prolonged or high-dose infusions.

Nesiritide is a recombinant B-type natriuretic peptide providing venodilation, arterial afterload reduction, and natriuresis via cGMP elevation without direct inotropic stimulation.

Calcium channel blockers are divided into dihydropyridines (potent vascular smooth muscle arterial vasodilators) and non-dihydropyridines (Diltiazem/Verapamil, which slow SA/AV node conduction and are contraindicated in HFrEF with EF <40%).

Ranolazine selectively inhibits the late inward sodium current (INa, late) in ischemic myocytes, reducing intracellular calcium overload and diastolic wall tension without affecting heart rate or blood pressure.

Last updated: August 2026

Vasodilator & Antianginal Pharmacology

Vasodilator and antianginal agents play a central role in managing Acute Coronary Syndromes (ACS), hypertensive emergencies, acute heart failure, and chronic stable angina. These medications decrease myocardial oxygen demand (MVO₂), augment myocardial oxygen supply, reduce cardiac filling pressures (preload), and lower systemic arterial resistance (afterload).

Organic Nitrates & Nitroglycerin Dynamics

Mechanism of Action: Nitroglycerin (NTG) and organic nitrates undergo intracellular enzymatic biotransformation (primarily via mitochondrial aldehyde dehydrogenase) to yield nitric oxide (NO). Nitric oxide diffuses into vascular smooth muscle cells, activating soluble guanylyl cyclase (sGC) to convert guanosine triphosphate (GTP) into cyclic guanosine monophosphate (cGMP). Elevated cGMP activates Protein Kinase G (PKG), promoting intracellular calcium reuptake and dephosphorylation of myosin light chains, culminating in vascular smooth muscle relaxation.

Dose-Dependent Hemodynamic Profile:

Low Infusion Rates (<100 mcg/min): Selectively dilate venous capacitance vessels. Venous pooling decreases venous return to the heart, lowering Left Ventricular End-Diastolic Volume (LVEDV), Left Ventricular End-Diastolic Pressure (LVEDP), and Pulmonary Capillary Wedge Pressure (PCWP). Decreasing LV volume lowers intramyocardial wall tension, substantially reducing MVO₂.

High Infusion Rates (>100 to 200 mcg/min): Dilation expands to systemic arterial resistance arterioles, producing significant reductions in SVR, MAP, and systolic blood pressure (afterload reduction).

Coronary Circulation Effects: Dilates epicardial coronary arteries, relieves coronary artery vasospasm, and enhances collateral blood flow to ischemic subendocardial myocardium.

Nitrate Tolerance & Management: Continuous, uninterrupted exposure to organic nitrates over 24–48 hours induces nitrate tolerance (tachyphylaxis). Proposed mechanisms include intracellular sulfhydryl group depletion, neurohormonal activation (RAAS/sympathetic overdrive), and oxidative stress inactivating mitochondrial aldehyde dehydrogenase. To prevent tolerance, a nitrate-free interval of 10 to 12 hours daily is mandatory for transdermal patches and long-acting oral nitrates (e.g., Isosorbide mononitrate/dinitrate).

Special AACN Nursing Mandates & Contraindications:

Polyvinyl Chloride (PVC) Absorption: Up to 80% of IV nitroglycerin binds to standard PVC plastic IV tubing and bags. Nitroglycerin continuous infusions MUST be prepared in glass bottles or polyolefin containers and administered using non-PVC polyethylene IV tubing.

Phosphodiesterase-5 (PDE-5) Inhibitor Absolute Contraindication: Concomitant administration of nitroglycerin with PDE-5 inhibitors (sildenafil, vardenafil within 24 hours; tadalafil within 48 hours) is strictly prohibited. PDE-5 inhibitors prevent cGMP breakdown; combining them with NO donors causes massive cGMP accumulation, precipitating profound, life-threatening, refractory hypotension and cardiac arrest.

Loading diagram... Sodium Nitroprusside Hemodynamic & Cyanide Toxicity Pathways

  • Sodium Nitroprusside, Natriuretic Peptides & Specific Vasodilators
  • 1. Sodium Nitroprusside (Nipride)

Mechanism of Action: Ultra-short-acting, balanced direct donor of nitric oxide that dilates both arterial resistance arterioles and venous capacitance vessels equally without requiring enzymatic conversion.

Clinical Indications: Hypertensive emergencies (aortic dissection, acute hypertensive encephalopathy), acute severe mitral regurgitation (rapid afterload reduction decreases regurgitant volume), acute aortic regurgitation, and refractory heart failure with severe vasoconstriction (SVR > 1600 dyn·s·cm⁻⁵).

Pharmacokinetics & Titration: Onset within <1 minute; duration of action 1–10 minutes. Continuous IV infusion initiated at 0.25 to 0.5 mcg/kg/min and titrated every 5 minutes up to a maximum of 10.0 mcg/kg/min.

Toxicity Profiles & Emergency Management:

Cyanide Toxicity: Nitroprusside contains 5 cyanide (CN⁻) ions per molecule. Free cyanide is buffered by hemoglobin and converted by hepatic rhodanase into thiocyanate using endogenous thiosulfate. High infusion rates (>2.0 mcg/kg/min for >24 hours) or hepatic dysfunction deplete thiosulfate, causing cyanide to bind mitochondrial cytochrome c oxidase. This halts aerobic respiration, driving severe anaerobic metabolism. Clinical signs include unexplained anion-gap metabolic acidosis, rising blood lactate, altered mental status, seizures, and elevated mixed venous oxygen saturation (SvO₂ > 80%, termed "venous hyperoxia" because tissues cannot extract oxygen). Treatment: Discontinue infusion; administer Hydroxocobalamin (Cyanokit, 5 g IV) , which binds cyanide to form cyanocobalamin (Vitamin B12), or Sodium Thiosulfate (12.5 g IV) .

Thiocyanate Toxicity: Thiocyanate (SCN⁻) is cleared renally with a half-life of 3–7 days. In patients with renal impairment (CrCl < 30 mL/min), thiocyanate accumulates, producing CNS toxicity: tinnitus, hyperreflexia, confusion, agitation, hallucinations, and seizures. Serum thiocyanate levels must be monitored (>10 mg/dL is toxic).

Light Sensitivity: Nitroprusside degrades rapidly upon light exposure; IV bags and tubing must be covered with opaque protective sleeves.

2. Nesiritide (Natrecor)

Mechanism of Action: Recombinant human B-type natriuretic peptide (rbNP). Binds to natriuretic peptide receptor-A (NPR-A) on vascular smooth muscle and vascular endothelium, elevating intracellular cGMP.

Hemodynamic & Renal Actions: Produces balanced arterial and venous vasodilation, reducing PCWP, LVEDP, and SVR. Promotes natriuresis and diuresis by inhibiting renal tubular sodium reabsorption and suppressing the Renin-Angiotensin-Aldosterone System (RAAS) and endothelin-1. Does NOT increase myocardial contractility or MVO₂.

Dosing & Monitoring: IV bolus of 2 mcg/kg over 1 minute followed by continuous infusion at 0.01 mcg/kg/min. Monitor closely for symptomatic hypotension and acute renal impairment.

3. Hydralazine & Isosorbide Dinitrate

Hydralazine: Direct-acting arterial vasodilator that inhibits IP₃-mediated calcium release from vascular smooth muscle sarcoplasmic reticulum. Selectively lowers SVR and afterload with minimal effect on venous capacitance. Triggers reflex sympathetic activation (tachycardia, elevated renin), requiring concurrent beta-blocker therapy.

Hydralazine + Isosorbide Dinitrate (BiDil): Combines arterial afterload reduction (hydralazine) with venous preload reduction (isosorbide dinitrate). Indicated as add-on therapy in self-identified African American patients with HFrEF (NYHA Class III-IV) or in patients intolerant to ACE inhibitors, ARBs, or ARNI due to renal failure or hyperkalemia.

4. Beta-Blockers, Calcium Channel Blockers & Ranolazine

Beta-Adrenergic Blockers:

Cardioselective (beta₁): Metoprolol succinate/tartrate, Atenolol, Esmolol, Bisoprolol.

Non-Selective / Combined α₁/beta1,2: Carvedilol, Labetalol.

Indications: ACS, stable HFrEF (Carvedilol, Metoprolol Succinate, Bisoprolol improve survival), AFib rate control. Decreases HR, contractility, AV conduction, and MVO₂. Contraindicated in acute decompensated heart failure with hypoperfusion ("cold and wet"), severe bradycardia, or 2nd/3rd-degree AV block.

Calcium Channel Blockers (CCBs):

Dihydropyridines (Amlodipine, Nicardipine, Clevidipine): Block L-type calcium channels in vascular smooth muscle → potent systemic arterial vasodilation with minimal nodal effects. Nicardipine IV and Clevidipine IV are first-line for most hypertensive emergencies and for acute stroke. They are not first-line in acute aortic syndromes: the 2022 ACC/AHA guideline requires an IV beta blocker first (Class 1) to lower dP/dt, with a vasodilator added only if blood pressure remains high afterward, because a pure arterial vasodilator given alone causes reflex tachycardia and raises aortic wall shear stress.

Non-Dihydropyridines (Diltiazem, Verapamil): Block L-type calcium channels in SA/AV nodes and myocardium → negative chronotropy, dromotropy, and inotropy. Primary indication: Rate control in atrial fibrillation. Absolutely contraindicated in HFrEF (LVEF < 40%) due to severe negative inotropic suppression.

Ranolazine (Ranexa):

Mechanism of Action: Selective inhibitor of the late inward sodium current (INa, late) in ischemic cardiomyocytes. Prevents intracellular sodium overload, thereby stopping reverse-mode Na⁺/Ca²⁺ exchanger overload. Reduces diastolic wall tension and enhances microvascular subendocardial perfusion without altering heart rate or blood pressure.

Indication: Chronic refractory angina.

Safety Monitoring: Causes dose-dependent QTc prolongation. Baseline ECG, serum potassium, and magnesium monitoring required; contraindicated with strong CYP3A4 inhibitors.